Experimental combo aims to tackle Treatment-Resistant cancers
NCT ID NCT07713732
First seen Jul 20, 2026 · Last updated Jul 22, 2026 · Updated 2 times
Summary
This early-stage trial tests whether an experimental drug called TLN-499, combined with the approved cancer drug venetoclax, is safe and tolerable for people with certain advanced solid tumors that have stopped responding to standard treatments. The study includes adults with small cell lung cancer, neuroendocrine cancer, malignant pleural mesothelioma, or synovial sarcoma. Researchers will monitor side effects, measure drug levels in the blood, and look for any signs that the tumors shrink.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a combination of an experimental drug called TLN-499 and a targeted cancer drug called venetoclax
- What this could lead to
- If this combination proves safe and shows signs of shrinking tumors, it could lead to a new treatment option for people with hard-to-treat solid cancers like small cell lung cancer and mesothelioma.
- What could go wrong
- This is a very early, first-in-human phase 1 trial, so the main goal is safety, not effectiveness. The combination may cause serious side effects or fail to control the cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT PLEURAL MESOTHELIOMAS (MPM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
COBL Clinical Trials - Christ O'Brien Lifehouse
Camperdown, New South Wales, 2050, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Cabrini Hospital Malvern
Malvern, Victoria, 3144, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Linear Clinical Research
Nedlands, Western Australia, 6009, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug cocktail aims to shrink Hard-to-Treat gut tumors
- New PET scan targets hidden lung cancer cells
- New drug THE-0504 enters human testing for tough cancers
- New cell therapy targets Hard-to-Treat cancers in first human trial
- Gene therapy safety check: 400 cancer patients monitored for years
- New drug IBI115 enters human testing for tough lung cancer